John M. Davis III, MD, MS, from the Mayo Clinic in Rochester, Minnesota, and Jennifer Gorman, MD, MPH, from The Polyclinic in Seattle, Washington, discuss the evolving collaborative care therapy model in RA.
Petros Efthimiou, MD, a rheumatologist at NYU Langone Health, discusses how clinicians should approach prescribing potentially teratogenic drugs in pregnancy.
Advances in the management of systemic lupus erythematosus have improved quality of life and outcomes for women who are considering pregnancy.
As a result of better management of rheumatoid arthritis, individuals with the condition are living longer. However, it is unknown if this represents different forms of the disease or a continuum of rheumatoid arthritis diagnosed at different stages.
Nonadherence to treatment regimens presents a barrier to optimal outcomes in RA and lupus.
Rapid expansion of effective therapies for psoriatic arthritis has driven new, ambitious treatment targets of minimal disease activity and disease remission.
Many variations of therapy for rheumatoid arthritis are now possible, and determining the optimal strategy for each patient is crucial to the success of treatment.
Fibromyalgia has remained a clinically nebulous entity, and one that is very difficult to manage effectively.
Thoracic manifestations are common in connective tissue disease, also called collagen vascular disease.
MRI allows to show changes to bone and cartilage, and to discriminate these from fluid and soft tissues around the joints, making it a good technique for measuring synovial volume and inflammation characteristic of RA.
